Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy
ObjectiveTo explore lymph node (LN)-related derived indicators as clinical cure markers for gastric cancer (GC) after gastrectomy.MethodsData of resected GC patients were extracted from the SEER database and our own department. Propensity score matching (PSM) was used to balance the baseline differe...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2023.1016252/full |
| _version_ | 1797830989802635264 |
|---|---|
| author | Jiebin Xie Yuan Zhang Ming He Xu Liu Jing Dong Pan Wang Yueshan Pang |
| author_facet | Jiebin Xie Yuan Zhang Ming He Xu Liu Jing Dong Pan Wang Yueshan Pang |
| author_sort | Jiebin Xie |
| collection | DOAJ |
| description | ObjectiveTo explore lymph node (LN)-related derived indicators as clinical cure markers for gastric cancer (GC) after gastrectomy.MethodsData of resected GC patients were extracted from the SEER database and our own department. Propensity score matching (PSM) was used to balance the baseline differences between the clinical cure and the nonclinical cure groups. The area under the curve (AUC) and decision curve analysis (DCA) were used to choose the optimal marker, and survival analysis was used to validate the clinical value of the most effective marker.ResultsAfter PSM, the differences in age, sex, race, location, surgical type, and histologic type between the two groups were significantly reduced (all P > 0.05), and the AUCs of examined LNs (ELNs), negative LNs (NLNs), ESR (ELNs/tumor size), ETR (ELNs/T-stage), NSR (NLNs/tumor size), NTR (NLNs/T-stage), EPR (ELNs/PLNs) and NPR (NLNs/PLNs) were 0.522, 0.625, 0.622, 0.692, 0.706, 0.751, 7.43, and 7.50, respectively. When NTR was 5.9, the Youden index of 0.378 was the highest. The sensitivity and specificity were 67.5% and 70.3% in the training group and 66.79% and 67.8% in the validation group, respectively. DCA showed that NTR had the largest net clinical benefit, and patients with NTR greater than 5.9 had significantly prolonged overall survival in our own cohort.ConclusionNLNs, NTR, NSR, ESR, ETR, NPR and EPR can be used as clinical cure markers. However, NTR was the most effective, and the best cutoff value was 5.9. |
| first_indexed | 2024-04-09T13:44:56Z |
| format | Article |
| id | doaj.art-b891eda3472047208e86fd759006edfb |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-04-09T13:44:56Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-b891eda3472047208e86fd759006edfb2023-05-09T05:27:51ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2023-05-011010.3389/fsurg.2023.10162521016252Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomyJiebin Xie0Yuan Zhang1Ming He2Xu Liu3Jing Dong4Pan Wang5Yueshan Pang6Department of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Gastrointestinal Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Geriatrics, Central Hospital of Nanchong, The Second Clinical School of North Sichuan Medical College, Nanchong, ChinaObjectiveTo explore lymph node (LN)-related derived indicators as clinical cure markers for gastric cancer (GC) after gastrectomy.MethodsData of resected GC patients were extracted from the SEER database and our own department. Propensity score matching (PSM) was used to balance the baseline differences between the clinical cure and the nonclinical cure groups. The area under the curve (AUC) and decision curve analysis (DCA) were used to choose the optimal marker, and survival analysis was used to validate the clinical value of the most effective marker.ResultsAfter PSM, the differences in age, sex, race, location, surgical type, and histologic type between the two groups were significantly reduced (all P > 0.05), and the AUCs of examined LNs (ELNs), negative LNs (NLNs), ESR (ELNs/tumor size), ETR (ELNs/T-stage), NSR (NLNs/tumor size), NTR (NLNs/T-stage), EPR (ELNs/PLNs) and NPR (NLNs/PLNs) were 0.522, 0.625, 0.622, 0.692, 0.706, 0.751, 7.43, and 7.50, respectively. When NTR was 5.9, the Youden index of 0.378 was the highest. The sensitivity and specificity were 67.5% and 70.3% in the training group and 66.79% and 67.8% in the validation group, respectively. DCA showed that NTR had the largest net clinical benefit, and patients with NTR greater than 5.9 had significantly prolonged overall survival in our own cohort.ConclusionNLNs, NTR, NSR, ESR, ETR, NPR and EPR can be used as clinical cure markers. However, NTR was the most effective, and the best cutoff value was 5.9.https://www.frontiersin.org/articles/10.3389/fsurg.2023.1016252/fullgastric cancerprognosisnegative lymph nodediagnostic markersnegative lymph node/T stage |
| spellingShingle | Jiebin Xie Yuan Zhang Ming He Xu Liu Jing Dong Pan Wang Yueshan Pang Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy Frontiers in Surgery gastric cancer prognosis negative lymph node diagnostic markers negative lymph node/T stage |
| title | Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy |
| title_full | Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy |
| title_fullStr | Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy |
| title_full_unstemmed | Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy |
| title_short | Development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy |
| title_sort | development and validation of a clinical cure marker based on negative lymph nodes for gastric cancer after gastrectomy |
| topic | gastric cancer prognosis negative lymph node diagnostic markers negative lymph node/T stage |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2023.1016252/full |
| work_keys_str_mv | AT jiebinxie developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy AT yuanzhang developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy AT minghe developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy AT xuliu developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy AT jingdong developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy AT panwang developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy AT yueshanpang developmentandvalidationofaclinicalcuremarkerbasedonnegativelymphnodesforgastriccanceraftergastrectomy |